Lung Cancer - Radiation Therapy

JANS Article

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and Multidisciplinary Management of Patients with Early-Stage Non-Small Cell Lung Cancer

June 15, 2023 | Cameron LindSilver Contributor

A new expert consensus on diagnosis, staging, and therapy for early-stage non-small cell lung cancer patients has been released. The experts recommend CT and PET imaging as a necessary part of the diagnosis and staging...

JANS Article

Personalized Magnetic Tentacles for Targeted Photothermal Cancer Therapy in Peripheral Lungs

October 12, 2023 | Jason Trevis

Lung cancer has the highest worldwide cancer mortality rate. Early non-small cell lung cancer accounts for 84 percent of cases, with curative surgical intervention being the standard treatment. The authors...

JANS Article

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and Multidisciplinary Management of Patients with Early-Stage Non-Small Cell Lung Cancer

June 15, 2023 | Cameron LindSilver Contributor

A new expert consensus on diagnosis, staging, and therapy for early-stage non-small cell lung cancer patients has been released. The experts recommend CT and PET imaging as a necessary part...

JANS Article

Lung Cancer in France

January 27, 2021 | Aristotle ProtopapasGold Commentor

An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer

...
JANS Article

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer

November 21, 2020 | Aristotle ProtopapasGold Commentor

A scholarly and sober narrative review on , as the authors state, a ‘ hot topic’ that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.

...
JANS Article

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

September 12, 2015 | Mark FergusonBronze Contributor

This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy. 232 pts...

JANS Article

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomized controlled trials – Part 1 of 9

August 20, 2015 | Lisa Brown

Thus far, only 3 randomized controlled trials (RCTs) have compared stereotactive ablative radiotherapy (SABR) versus surgery in patients with early stage NSCLC (STARS trial, ROSEL trial, and ACOSOG Z4099 trial)....

JANS Article

SABR in early operable lung cancer: time for evidence – Part 2 of 9

August 20, 2015 | Lisa Brown

This is an invited commentary on the article by Chang and colleagues (Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised...

JANS Article

Lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? – Part 3 of 9

August 20, 2015 | Lisa Brown

This expert opinion editorial is published in JTCVS in response to the article by Chang and colleagues. Meyers and colleagues begin by emphasizing that a large randomized controlled trial (RCT)...

JANS Article

Surgery versus SABR for resectable non-small-cell lung cancer – Part 4 of 9

August 20, 2015 | Lisa Brown

This is a letter in response to the article by Chang and colleagues. The authors point out that only 58 patients were enrolled from 38 centers over 66.3 months, and...

JANS Article

Surgery versus SABR for resectable non-small-cell lung cancer – Part 5 of 9

August 20, 2015 | Lisa Brown

This is a letter in response to the article by Chang and colleagues. The authors focus on two key points: the difference in 3-year survival between the two treatment groups...

JANS Article

Surgery versus SABR for resectable non-small-cell lung cancer – Part 6 of 9

August 20, 2015 | Lisa Brown

This is a letter in response to the article by Chang and colleagues. The authors warn to interpret the findings of the original article, that SABR is better tolerated and...

JANS Article

Surgery versus SABR for resectable non-small-cell lung cancer – Part 7 of 9

August 20, 2015 | Lisa Brown

This is a letter in response to the article by Chang and colleagues. The authors begin by stating that the data from this study should be graded according to an...

LOAD MORE
ADVERTISE ON CTSNET